Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity: 2016-2020

Historic Liabilities and Shareholders Equity for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $18.2 million.

  • Monopar Therapeutics' Liabilities and Shareholders Equity rose 255.40% to $18.2 million in Q3 2020 from the same period last year, while for Sep 2020 it was $57.1 million, marking a year-over-year increase of 134.46%. This contributed to the annual value of $13.4 million for FY2019, which is 82.46% up from last year.
  • Per Monopar Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $18.2 million for Q3 2020, which was up 41.81% from $12.8 million recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Liabilities and Shareholders Equity registered a high of $18.2 million during Q3 2020, and its lowest value of $2.9 million during Q4 2016.
  • For the 3-year period, Monopar Therapeutics' Liabilities and Shareholders Equity averaged around $9.7 million, with its median value being $8.4 million (2018).
  • Per our database at Business Quant, Monopar Therapeutics' Liabilities and Shareholders Equity plummeted by 35.23% in 2019 and then spiked by 255.40% in 2020.
  • Quarterly analysis of 5 years shows Monopar Therapeutics' Liabilities and Shareholders Equity stood at $2.9 million in 2016, then surged by 242.98% to $9.9 million in 2017, then declined by 26.31% to $7.3 million in 2018, then soared by 82.46% to $13.4 million in 2019, then soared by 255.40% to $18.2 million in 2020.
  • Its Liabilities and Shareholders Equity stands at $18.2 million for Q3 2020, versus $12.8 million for Q2 2020 and $12.8 million for Q1 2020.